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Antibiotic resistance in bacteria incurs fitness cost, but compensatory mechanisms may
ameliorate the cost and sustain the resistance even under antibiotics-free conditions. The
aim of this study was to determine compensatory mechanisms of antibiotic resistance in
H. pylori. Five strains of levofloxacin-sensitive H. pylori were induced in vitro to develop
resistance. In addition, four pairs of metronidazole-sensitive and -resistant H. pylori
strains were isolated from patients carrying dual H. pylori populations that consist of
both sensitive and resistant phenotypes. Growth rate, virulence and biofilm-forming
ability of the sensitive and resistant strains were compared to determine effects of
compensatory response. Proteome profiles of paired sensitive and resistant strains
were analyzed by liquid chromatography/mass spectrophotometry (LC/MS). Although
there were no significant differences in growth rate between sensitive and resistant
pairs, bacterial virulence (in terms of abilities to induce apoptosis and form biofilm)
differs from pair to pair. These findings demonstrate the complex and strain-specific
phenotypic changes in compensation for antibiotics resistance. Compensation for in vitro
induced levofloxacin resistance involving mutations of gyrA and gyrB was functionally
random. Furthermore, higher protein translation and non-functional protein degradation
capabilities in naturally-occuring dual population metronidazole sensitive-resistant strains
may be a possible alternative mechanism underlying resistance to metronidazole without
mutations in rdxA and frxA. This may explain the lack of mutations in target genes in
∼10% of metronidazole resistant strains.
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INTRODUCTION
Helicobacter pylori is a common bacterial pathogen that colonize the human stomach and is related
to incidence of gastric cancer and peptic ulcer diseases (Parsonnet et al., 1991; Dhar et al., 2003).
H. pylori infection can often be successfully eradicated with antibiotics (Heo and Jeon, 2014).
However, the increasing prevalence of antibiotic resistance in H. pylori is a cause of concern
as this is one of the most important causes of therapy failure (Graham and Fischbach, 2010).
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The prevalence of H. pylori antibiotic resistance has been
associated with extensive use of antibiotics within a population
(Megraud and Lehours, 2007; de Francesco et al., 2010).
The antibiotics used to treat H. pylori infection were mainly
amoxicillin, clarithromycin, and metronidazole; these would
be administered for 10–14 days in combination with an anti-
secretory drug to increase the pH (Lind et al., 1999). Current
recommendations for H. pylori treatment include the first
line therapy, which is standard triple therapy consisting a
combination of proton pump inhibitors (PPI), clarithromycin,
and amoxicillin or metronidazole; the second line therapy will
be used in the case of treatment failure, in which bismuth-based
quadruple therapy or levofloxacin-containing triple therapy are
recommended (Malfertheiner et al., 2007).
Levofloxacin, a fluoroquinolone, was shown to have
eradicated H. pylori effectively (Cammarota et al., 2000).
Fluoroquinolones generally target chromosome replication and
in particular, DNA gyrase, which allows DNA unraveling before
replication. However, the prevalence of levofloxacin resistance
in H. pylori has been increasing worldwide (de Francesco et al.,
2010); with resistance rates at 14.1% in Europe (Megraud et al.,
2013), 20.6% in southeast region of China (Su et al., 2013),
and 18.4% in Vietnam (Binh et al., 2013). This resistance has
been associated with the point mutations occurring at positions
Asn87 and Asp91 of the quinolone resistance determining region
(QRDR) within gyrA gene (Miyachi et al., 2006; Rozen et al.,
2007; Lee et al., 2011). Other mutations that have also been
linked to levofloxacin resistance include mutations at positions
Ala88, Ala97, and Met191 of gyrA and Phe438, Asp481, and
Arg484 of gyrB (Miyachi et al., 2006; Liu et al., 2011; Teh et al.,
2014).
Metronidazole, a nitroimidazole, acts as a biocidal agent by
its interaction with a nitroreductase homolog, RdxA. Reduction
of metronidazole results in the formation of DNA-damaging
and mutagenic products (Sisson et al., 2000). Mutations in
rdxA were shown to be the cause of H. pylori resistance to
metronidazole (Goodwin et al., 1998). Inactivation of rdxA
reduces the effect of nitroreductases, which comes with the
decrease of conversion of metronidazole into hydroxylamine that
damages bacterial DNA (Olekhnovich et al., 2009). Mutation in
another gene, frxA, encoding for NADH flavin oxidoreductase,
was also implicated in H. pylori metronidazole resistance (Kwon
et al., 2000). FrxA, another nitroreductase of H. pylori, may also
activate metronidazole bactericidal action although the overall
effects of frxA mutation are still being investigated (Justino
et al., 2014). Mutations, such as frameshift, missense, premature
truncations, deletions, and insertions within rdxA and frxA
genes, are associated with metronidazole resistance (Kwon et al.,
2000; Teh et al., 2014; Binh et al., 2015). In an earlier study, it was
shown that 4/37 (10.8%) of the metronidazole resistant H. pylori
strains from Malaysia could not be attributed to mutations in
rdxA and/or fdxA (Teh et al., 2014). Thus, H. pylorimay become
resistant to the antibiotic via other mechanisms.
Despite the studies on the resistance-related genes, the
consequences of mutations on the physiological state ofH. pylori
are poorly understood. The impact of mutation in antibiotic
resistance has been studied in vitro in Streptococcus pneumoniae
for levofloxacin resistance; different resistance-encoding genes
were shown to cost different levels of fitness (Rozen et al.,
2007). Björkholm et al. (2001) studied the biological cost
of mutation in response to clarithromycin resistance in H.
pylori; compensatory mutation has been suggested to affect
bacterial fitness. However, the effects of mutations that result in
levofloxacin and metronidazole resistance have not been studied
inH. pylori. Furthermore, antibiotic resistance-related mutations
may affect bacterial virulence and survival. Implications of
mutations in H. pylori virulence proteins involved in apoptosis
(Oldani et al., 2009) and biofilm formation (Cole et al., 2004)
have been studied. Maintenance of plasmids and mutated
virulence genes cost energy (Martínez and Baquero, 2002).
Therefore, in the absence of antibiotic selective pressure, higher
level of virulence may still be maintained for the survival of
bacteria could be attributed to the development of compensatory
mutations (Martínez and Baquero, 2002). Analysis of H. pylori
proteome may reveal patterns of compensatory mutations in
response to metronidazole and fluoroquinolone resistance. An
objective of this study was to determine the proteome of resistant
H. pylori in response to amelioration of fitness cost as part of a
compensatory response.
MATERIALS AND METHODS
Induction of Levofloxacin Resistant Strains
H. pylori strains sensitive to levofloxacin were incubated at
37◦C in a microaerophilic atmosphere of 10% CO2. They
were inoculated into BHI broth with a series of levofloxacin
concentrations (0.0156, 0.0313, 0.0625, 0.125, 0.25, 0.5, 1, 2,
4, 8) in a 96-well plate. After each passage, the cells would
be exposed to increased concentration of levofloxacin. For
example, the cells grew in the broth with 0.0156 µg/ml
levofloxacin would be inoculated to the broth with 0.0313
µg/ml in the next growth passage. The bacterial suspensions
were transferred to antibiotics-free chocolate agar to determine
the minimum inhibitory concentration (MIC) of levofloxacin
after each exposure. Stable induced-resistant strains would be
grown on chocolate agar supplemented with levofloxacin to
confirm resistance. The identity between resistant strains and
their corresponding parental sensitive strains before induction
were verified by random amplification of polymorphic DNA-
polymerase chain reaction (RAPD-PCR) typing using primers
1254 and 1281 as described by Akopyanz et al. (1992) with
the following modifications. The reaction mix (Thermo Fisher
Scientific, USA) consisted of 1 × Taq buffer with KCl, 0.4 mM
of each deoxynucleotide triphosphates (dNTPs), 3 mMMgCl2, 1
U TaqDNA polymerase, 0.2µMof RAPD primer, 10 ng genomic
DNA in a volume of 25 µl. The conditions for PCR amplification
were denaturation at 95◦C for 3 min, followed by 35 cycles of
95◦C for 1min, 38◦C (for primer 1254) or 32◦C (for primer 1281)
for 1 min, 72◦C for 2 min; and then a final extension at 72◦C for
5 min.
Screening for Dual Population
Metronidazole-Sensitive and Resistant
Strains
For in vitro susceptibility testing of the H. pylori strains, a
suspension equal to the McFarland tube no. 3 was prepared for
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each strain in BHI broth supplemented with 2% β-cyclodextrin
and 0.4% yeast extract. The cell suspension was inoculated by
confluent swabbing of the surface of non-selective chocolate
agar with the adjusted inoculum suspensions. Metronidazole
discs were laid on the agar surface. The plates were then
be incubated at 37◦C under microaerophilic conditions. The
breakpoint zone diameter was recorded after 48–72 h of
incubation. Colonies that grew within clear zones were isolated
and grown on metronidazole-supplemented chocolate agar to
confirm resistance. Colonies that grew around the clear zones
were isolated and grown on non-selective and metronidazole-
supplemented chocolate agar to confirm susceptibility. Resistant
and susceptible isolates of the same strain from the antibiotics
screening were selected for dual population study. Genomic DNA
of H. pylori was extracted for PCR amplification and sequencing
of gyrA, gyrB, rdxA, and frxA, which were performed as described
by Teh et al. (2014).
H. pylori Strains and Growth
The H. pylori UM137, UM171, UM229, UM233, UM276
which consist of levofloxacin-sensitive and induced-resistant
variant of each strain, and UM163, UM303, UM400, UM443
which consist of metronidazole-sensitive and naturally-occuring
resistant variants of each strain were used in this study. UM276
was also resistant to metronidazole and UM229 was additionally
resistant to clarithromycin. The 18 strains of H. pylori were
categorized into sensitive and resistant groups based on their
resistance to metronidazole, levofloxacin, clarithromycin, and
multi-drug resistance (Figure 1). The H. pylori strains were
cultured on chocolate agar for 3 days inmicroaerobic atmosphere
at 37◦C and the cells were harvested for protein extraction.
Optical Density and Viable Count
H. pylori strains exhibiting dual phenotypes (sensitive
and resistant) were incubated respectively in BHI broth
FIGURE 1 | H. pylori strains according to sensitivity or resistance to
metronidazolea, levofloxacin, clarithromycinb, and combined
(multi-drugc) resistance. aUM276 and UM276L (levofloxacin-sensitive and
resistant), UM163M, UM303M, UM400M, UM443M have naturally-occuring
resistance to metronidazole. bUM229 and UM229L (levofloxacin-sensitive and
resistant) has naturally-occuring resistance to clarithromycin. cResistant to
metronidazole, levofloxacin, and/or clarithromycin.
supplemented with 10% fetal bovine serum and 0.4% yeast extract
in a microaerobic atmosphere at 37◦C. At t = 0 h, the optical
density (OD) of the H. pylori suspensions was standardized to
be at the same level at 600 nm by spectrophotometry. Samples
were collected every 24 h over 7 days. The OD600 of the cell
suspension was measured by spectrophotometry and viable
count was performed to compare their growth curves; a serial
dilution of the incubated samples was performed and the number
of colony-forming units (CFU) was assessed after each time
interval.
Apoptosis Assay
AGS cells, a gastric epithelial cell line, were infected in vitro
withH. pylori susceptible- and its corresponding resistant-strains
at a multiplicity of infection (MOI) of 50:1 bacteria to cell
(Menaker et al., 2004). H. pylori was removed and the infected
AGS cells were harvested at time intervals of t = 4, 8, and
12 h. The cells were stained with Annexin V Alexa Fluor R© 488
and propidium iodide according to the instructions in Tali R©
apoptosis kit (Thermo Fisher Scientific). Annexin V-positive and
propidium iodide-negative cells were considered as apoptotic
cells (Sawai and Domae, 2011). The levels of apoptosis induced
by the antibiotics-resistant H. pylori strain and its parental
susceptible strain were compared using Tali R© image-based
cytometer (Thermo Fisher Scientific). Apoptosis induction is an
indicator of the H. pylori virulence activity (Cho et al., 2003).
Biofilm Measurement
Various strains of H. pylori cultured on chocolate agar for 3 days
were harvested and incubated for another 3 days in BHI broth
supplemented with 2% β-cyclodextrin and 0.4% yeast extract.
The total bacterial population for the cultures was standardized
at the same OD600 value. A volume of 2 ml of each bacterial
suspension was inoculated into each well of a 24-well plate. The
growth of biofilm was observed after every 24 h over 7 days
of incubation at 37◦C in 10% CO2; the bacterial suspension
was aspirated and 0.1% crystal violet was added into the well.
The plate was gently agitated for 30 min and the crystal violet
was removed. The crystal violet-treated wells were washed with
distilled water and the stained biofilm was destained with 19:1
ethanol-acetic acid. The destaining solution was collected and
its absorbance was measured at OD600. The amount of biofilm
produced by antibiotic-resistant H. pylori strain and its sensitive
strain was compared. The ability to form biofilm indicates the
ability to survive against the activity of biocidal agents (Yonezawa
et al., 2010).
Protein Extraction and Mass Spectrometry
H. pylori cell pellets were lysed and its protein was extracted using
Norgen’s ProteospinTM total protein purification kit (Norgen
Biotek Corporation, Canada). Cells were resuspended in 50
µl lysis buffer and centrifuged at 14,000 × g for 2 min. The
supernatant was transferred into a filter column fitted in an
elution tube, and centrifuged at 14,000 × g for 1 min. One
microliter of protease inhibitor (Halt Protease and Phosphatase
Inhibitor; Thermo Fisher Scientific) was added to the tube.
Protein concentrations were determined by Bradford assay
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(Bio-Rad, USA). Each tube of protein sample was reduced with
a volume of 10 mM dithiothreitol (DTT; Bio-Rad), and alkylated
in the dark with a volume of 20 mM iodoacetamide (IAA;
Bio-Rad). The samples were incubated at room temperature
for 30 min and added with PierceTM trypsin protease (Thermo
Scientific) to digest the proteins at 1:50 trypsin:protein. The
samples were then incubated at 4◦C for 30 min, and subsequently
at 37◦C for overnight. The extracted protein was then treated for
liquid chromatography mass spectrophotometry according to a
previous study (Chan et al., 2015).
Protein Profiling and Identification
Raw data was exported and sequencing was performed using
PEAKS software (version 7.5; Bioinformatics Solution Inc.,
ON, Canada). The reference proteome database was H.
pylori J99. Results were refined by using a false discovery
rate (FDR) of 1%, and 1 unique peptide according to
metronidazole- and levofloxacin-sensitive and resistant strain
groups (Supplementary Material).
Proteins common to all strains in each group were selected
(levofloxacin-sensitive, levofloxacin-resistant, metronidazole-
sensitive, metronidazole-resistant) for protein expression
analysis. Protein-protein interaction networks were analyzed
by using STRING 10 (Szklarczyk et al., 2015). Proteins which
were differentially expressed between sensitive and resistant
groups were further analyzed for their functions in molecular
and biological functions from UniProt database (The Uniprot
Consortium, 2008) and pathways from KEGG database
(Kanehisa et al., 2014), and possible roles in compensatory
response.
Independence Test of Resistance and
Genes
The up- or down-regulation of all expressed proteins in each
strain was scored, and the difference between antibiotic-sensitive
and -resistant strain groups was determined in terms of fold-
expression. Proteins with the difference in scores of between
0.5- and 2 fold-difference were eliminated. The independence
test of association between antibiotics resistance and the genes
corresponding to the expressed proteins was determined by
Fisher’s exact test which was performed using SPSS (version
20; SPSS Inc, Chicago, USA). The antibiotics resistance in this
test refers to the resistance against levofloxacin, metronidazole,
clarithromycin or the combination resistance of any of the
antibiotics (levofloxacin and clarithromycin, or levofloxacin, and
metronidazole).
RESULTS AND DISCUSSION
The emergence of resistant bacteria as a result of adaptability
to antibiotics has no doubt been an emerging concern for
human health. In turn, resistant bacteria presumably gained
mutations that could ameliorate the reduced fitness as a
result of its adaptation to antibiotics. These mutations were
considered to be involved in compensatory mechanism that
compensates for the fitness lost due to resistance (Handel
et al., 2006). Compensatory mutations could occurred in
regions of the genome due to selective pressure to compensate
for the deleterious effects of the initial resistance mutations
(Maisnier-Patin and Andersson, 2004). These mutations may
be involved in any particular molecular or biological functions.
A proteomic study on metronidazole-resistant H. pylori had
examined metabolic changes in the bacteria which reported
down- and up-regulation of various proteins including a
protein with reductase activity (McAtee et al., 2001). The
protein composition of the antibiotics resistant H. pylori may
reveal the biological pathways involved in a compensatory
response.
Functional Characteristics
Based on MIC, strains were considered to be levofloxacin-
sensitive (<1 µg/ml) or resistant (≥1 µg/ml; Chisholm and
Owen, 2009); or metronidazole-sensitive (<8 µg/ml) or resistant
(≥8 µg/ml; Osato et al., 2001). Five levofloxacin-sensitive H.
pylori strains with MIC≤ 0.125 µg/ml were successfully induced
in vitro to become resistant with MIC > 32 µg/ml, while four
pairs of naturally-occurring metronidazole-resistant H. pylori
strains with MIC > 256 µg/ml and metronidazole-sensitive
TABLE 1 | MICs of H. pylori strains before and after levofloxacin-resistance in vitro induction (UM137, UM171, UM229, UM233, and UM276) and
naturally-occuring metronidazole-sensitive and resistant H. pylori strains (UM163, UM303, UM400, UM443).
H. pylori Strains Levofloxacin/metronidazole MIC before induction/sensitive
(µg/ml)
MIC after induction/resistant
(µg/ml)
UM137 and UM137L Levofloxacin-resistance (induced) 0.064 >32
UM171 and UM171L Levofloxacin-resistance (induced) 0.094 >32
UM229b and UM229L Levofloxacin-resistance (induced) 0.032 >32
UM233 and UM233L Levofloxacin-resistance (induced) 0.125 >32
UM276a and UM276L Levofloxacin-resistance (induced) 0.125 >32
UM163 and UM163M Metronidazole-resistance (naturally-occurring dual population) 0.5 >256
UM303 and UM303M Metronidazole-resistance (naturally-occurring dual population) 0.75 >256
UM400 and UM400M Metronidazole-resistance (naturally-occurring dual population) 0.5 >256
UM443 and UM443M Metronidazole-resistance (naturally-occurring dual population) 0.75 >256
aUM229 and UM229L (levofloxacin-sensitive and resistant) has naturally-occuring resistance to clarithromycin.
bUM276 and UM276L (levofloxacin-sensitive and resistant), UM163M, UM303M, UM400M, UM443M have naturally-occuring resistance to metronidazole.
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strains with MIC ≤ 0.75 µg/ml were isolated for this study
(Table 1). These four pairs of metronidazole-sensitive and -
resistant strains were isolated after screening through 170 H.
pylori positive gastric tissue biopsies collected from patients seen
at the Endoscopy Unit (University of Malaya Medical Centre,
Kuala Lumpur, Malaysia) during the period from July 2011
to June 2014. All pairs of sensitive and resistant strains for
both antibiotics were verified to be identical by RAPD-PCR
genotyping (Figure 2).
Determination of growth rate and generation time is
often used to measure fitness costs associated with antibiotic
resistance (Pope et al., 2010). The growth curves of these
five pairs of levofloxacin-sensitive and resistant, and four pairs
of metronidazole-sensitive and resistant H. pylori strains were
not significantly different within pairs (p ≥ 0.05; Figure 3).
Thus, change in antibiotics resistance status did not reduce the
growth fitness of the resistant strains compared to its sensitive
counterparts. However, a limitation of growth curve is that
the competitive fitness of sensitive strains over its resistant
counterparts could not be assessed.
Among the nine pairs of sensitive and resistant strains, only
three pairs of dual strains showed significant change in their
ability to induce apoptosis in AGS cells within pairs (p <
0.05). The level of apoptotic AGS cells induced by H. pylori
infection post-12 h showed a decrease in the metronidazole
resistant strains, UM163M and UM303M, and an increase
in the resistant strain, UM400M, compared to their sensitive
counterparts (Table 2). In contrast, none of the levofloxacin
FIGURE 2 | RAPD-PCR typing of (A) levofloxacin-induced H. pylori UM137 strains 1–8 sensitive, 9–12 resistant (B) metronidazole dual population of H. pylori
UM163 strains 13–19 sensitive, 20–22 resistant. Primers used were 1254 and 1281, and M: 1 kb DNA ladder.
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FIGURE 3 | Growth curves of (A) UM137 (B) UM171 (C) UM229 (D) UM233 (E) UM276 (F) UM163 (G) UM303 (H) UM400 (I) UM443 H. pylori strains. Data
represent mean ± SEM (n = 3).
TABLE 2 | Fold differences of the apoptotic AGS cells population induced
by H. pylori from the ratio of resistant and sensitive pair strains, post-12 h
of infection.
Strain Fold difference of apoptotic cells population
(resistant:sensitive pair strain)
UM137 and UM137L 1.33
UM171 and UM171L 1.00
UM229 and UM229L 1.33
UM233 and UM233L 0.83
UM276 and UM276L 1.25
UM163 and UM163M 0.33*
UM303 and UM303M 0.25*
UM400 and UM400M 3.50*
UM443 and UM443M 1.50
*Fold difference <0.5 and >2.0 is considered to have undergone significant change.
resistant strains showed significant change in ability to induce
apoptosis compared to their sensitive counterparts. Uninfected
cells acted as negative control while staurosporine-treated AGS
cells act as the positive control (four-fold increase in apoptosis
compared to untreated AGS cells).
At population level, biofilm formation is a multicellular
strategy for survival, and indirectly increases overall bacterial
survival fitness. Bacterial biofilm presents as a physiological
barrier at stationary growth phase against antibiotics whereby
viable cells may persist due to the impenetrable structural matrix,
the equilibrium of live and dead cells, or the regulation of
genes expression (Normark and Normark, 2002). A majority
of these strains were low-level biofilm formers, except for
UM137, UM163, UM171, and UM443, and fold changes
between the resistant and sensitive strains in the low-level
biofilm forming pairs were not significantly different (p ≥
0.05) (Table 3). Among the high-level biofilm forming strains,
UM137L showed a significant decrease in biofilm formed. On
the other hand, UM443M showed no significant increase of the
biofilm formed over 7 days (p ≥ 0.05), while the biofilm formed
by UM163M and UM171L were decreased compared to UM163
and UM171 respectively; the fold change did not reach statistical
significance (p ≥ 0.05).
Molecular Characteristics
GyrA mutations occurred in the QRDR of the induced
levofloxacin-resistant strains at N87K for UM137L and UM276L,
A88V for UM233L, and D91N for UM171L and UM229L,
D155N for UM137L and UM233L whereas substitutions S429T
and R484K occurred in gyrB of UM233L (Figure 4). On the
other hand, no specific mutations occurred in naturally-occuring
metronidazole resistant strains, except for A40V in frxA of
UM443M. Thus, in vitro induction of levofloxacin resistance
could be explained by known gyrA and/or gyrB mutations
while the naturally-occurring dual population metronidazole
resistance could be caused by mutations in other genes or may
involve other mechanisms.
Inter-Gene or Intra-Molecular Protein
Interactions
In order to explore the underlying compensatory mechanisms
adopted by antibiotic resistant H. pylori to maintain their overall
Frontiers in Microbiology | www.frontiersin.org 6 December 2016 | Volume 7 | Article 2015
Hanafi et al. H. pylori Levofloxacin and Metronidazole Resistance
TABLE 3 | Average biofilm formation of H. pylori strains over 7 days of
growth and the fold difference between resistant and sensitive
pair strains.
Strain Average amount of
biofilm formation
Fold difference of the amount of biofilm
formation (resistant:sensitive pair strain)
UM137 0.744 0.240#
UM137L 0.178
UM171 0.796 0.777#
UM171L 0.618
UM229 0.039 3.259
UM229L 0.126
UM233 0.158 0.184
UM233L 0.029
UM276 0.092 1.348
UM276L 0.124
UM163 0.420 0.723#
UM163M 0.304
UM303 0.098 1.058
UM303M 0.104
UM400 0.020 4.627
UM400M 0.091
UM443 0.258 2.004#
UM443M 0.518
#High-level biofilm former strains.
fitness, protein profiling on the nine pairs of sensitive and
resistant H. pylori strains was performed. All expressed proteins
with significant association with levofloxacin, metronidazole,
clarithromycin, and/or any combination of them (levofloxacin
and clarithromycin, or levofloxacin, and metronidazole) were
identified using Fisher’s Exact test with p < 0.05 considered to
be significant (Table 4).
From the prediction of possible protein-protein interactions
by STRING, changes in protein expression profiles of
metronidazole-resistant strains appeared to be functionally
related compared to levofloxacin-resistant strains (Figure 5).
Metronidazole resistance associated proteins are involved in
translation, ATP binding, ligase activity, aminoacyl-tRNA editing
activity, rRNA binding, or structural constituent of ribosome
(Table 5). These up-regulated proteins may either represent an
alternative mechanism of metronidazole resistance in a dual
population environment without genetic mutations in rdxA
and frxA and/ or as a compensatory mechanism underlying
metronidazole resistance. The alteration in protein profile
may explain the dual population phenomenon whereby some
bacterial cells were more resistant to antibiotics than others
despite having similar genetic makeup.
It has been suggested that the presence of different proteins
in strains with different antibiotic resistance may be attributed
to epistasis (Salverda et al., 2011). The effect of compensatory
response against antibiotic resistance may be due to the
interactions between the primary resistance genes and the
secondary mutated genes (Moore et al., 2000; Baker et al., 2013).
In addition, the association of genes with the sensitive-resistant
groups of different antibiotic groups may be due to the effect
FIGURE 4 | Amino acid sequences of levofloxacin
resistance-associated gene regions: (A) gyrA, (B) gyrB, and metronidazole
resistance-associated gene regions: (C) rdxA, (D) frxA of H. pylori strains. gyrA
and gyrB sequences were compared to UM038 strain (positive gyrA mutation),
and rdxA and frxA sequences were compared to a reference strain, 26695.
Positions of expected mutations associated with levofloxacin are in box
outlines, and positions of variations of mutation in either antibiotic-resistant
strains are in gray boxes.
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TABLE 4 | Proteins of significant association with resistance to metronidazole, levofloxacin, and/or clarithromycin in all of the 18 H. pylori strains tested
using Fisher’s exact test (2-tailed, p < 0.05 is considered significant).
Protein Protein description/function Antibiotic resistance Fisher’s exact test (p-value)
UvrB UvrABC system protein B Levofloxacin 0.014
Jhp_0525 Putative protein Levofloxacin 0.031
Jhp_0602 Putative processing protease Levofloxacin 0.031
Jhp_0260 Putative protein Levofloxacin 0.032
CarB Carbamoyl-phosphate synthase large chain Levofloxacin 0.033
ClpP Chaperone protein Metronidazole 0.007
Jhp_0892 Putative protein Metronidazole 0.007
SerA (Jhp_0984) D-3-phosphoglycerate dehydrogenase Metronidazole 0.007
Efp (Jhp_0163) Elongation factor P Metronidazole 0.022
HypB (Jhp_0837) Hydrogenase/urease nickel incorporation protein HypB Metronidazole 0.022
IleS (Jhp_1317) Isoleucine-tRNA ligase Metronidazole 0.022
ProS (Jhp_0067) Urease subunit beta Metronidazole 0.022
RplF (Jhp_1224) 50S ribosomal protein L6 Metronidazole 0.022
RpsS (Jhp_1235) 30S ribosomal protein S19 Metronidazole 0.022
PyrF (Jhp_0005) Orotidine 5′-phosphate decarboxylase Metronidazole 0.031
RpsI (Jhp_0076) 30S ribosomal protein S9 Metronidazole 0.031
Jhp_0844 Flagellar basal body protein Metronidazole, levofloxacin 0.042
Jhp_1071 Putative protein Metronidazole, levofloxacin 0.042
Jhp_1303 Putative protein Metronidazole, levofloxacin 0.042
CysS (Jhp_0818) Cysteine-tRNA ligase Metronidazole, levofloxacin 0.042
These proteins were up-regulated in the levofloxacin and metronidazole resistant H. pylori strains.
FIGURE 5 | STRING protein-protein interaction network of proteins from PEAKS refined data. The gene names correspond with the proteins that were
recovered from (A) levofloxacin and (B) metronidazole-sensitive and resistant strains.
of either positive or negative epistasis (Schenk et al., 2013). It
may also be possible that these compensatory protein responses
are in the vicinity of their expressed resistance mutations in
their primary or tertiary protein structure (Davis et al., 2009).
This may explain the levofloxacin sensitive strains protein
expression profile, which seem to be functionally random, as
compared to that of the metronidazole resistant strains. Afterall,
point mutations in gyrA and gyrB, which are responsible for
levofloxacin resistence, also occurred at random positions along
the genes. These point mutations at different positions may alter
the interaction and functions of these proteins differently.
Protein Translation of Antibiotic Resistant
Strains
ProS, IleS, and CysS are aminoacyl-tRNA ligases (also known as
aminoacyl-tRNA synthetases) that are involved in the synthesis
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TABLE 5 | Proteins with differential expression among nine pairs of levofloxacin and metronidazole-resistant and sensitive strains.
Gene/Protein Molecular function Biological process Pathway (KEGG pathway)
proS/Proline–tRNA ligase Aminoacyl-tRNA editing activity, ATP binding,
proline-tRNA ligase activity
Prolyl-tRNA aminoacylation Aminoacyl-tRNA biosynthesis (970)
ileS/Isoleucine–tRNA ligase Aminoacyl-tRNA editing activity, ATP binding,
isoleucine-tRNA ligase activity, zinc ion
binding
Isoleucyl-tRNA aminoacylation Aminoacyl-tRNA biosynthesis (970)
cysS/Cysteine–tRNA ligase ATP binding, cysteine-tRNA ligase activity,
zinc ion binding
Cysteinyl-tRNA aminoacylation Aminoacyl-tRNA biosynthesis (970)
rpsS/30S ribosomal protein S19 rRNA binding, structural constituent of
ribosome
Translation Ribosome (3010)
rplF/50S ribosomal protein L6 rRNA binding, structural constituent of
ribosome
Translation Ribosome (3010)
rpsI/30S ribosomal protein S9 Structural constituent of ribosome Translation Ribosome (3010)
serA/D-3-phosphoglycerate
dehydrogenase
Amino acid binding, NAD binding,
phosphoglycerate dehydrogenase activity
L-serine biosynthetic process Metabolic pathways (1100)
pyrF/Orotidine 5′-phosphate
decarboxylase
Orodotine-5′-phosphate decarboxylase
activity
“de novo” pyrimidine nucleobase biosynthetic
process, “de novo” UMP biosynthetic process
Metabolic pathways (1100)
jhp_0844/Putative flagellar
basal-body/rod/hookprotein
Bacterial-type flagellum-dependent cell motility Flagellar assembly (2040)
These proteins were up-regulated in the levofloxacin and metronidazole resistant H. pylori strains.
of aminoacyl-tRNAs, which bind to ribosomes during the
translation process (Hendrickson and Schimmel, 2003). In
the current study, these aminoacyl-tRNA synthetases were
found to be expressed in metronidazole resistant H. pylori
strains (except CysS that was also expressed in levofloxacin
resistant strains) but not in sensitive strains. In Clostridium
difficile, aminoacyl-tRNA synthetases, CysS, and SerS, were
highly expressed in bacterial strains that exhibit resistance
to metronidazole (Moura et al., 2014). Interestingly, it was
also shown that these aminoacyl-tRNA synthetases were not
detected the same metronidazole-resistant C. difficle when
cultured in the presence of the antibiotic (Moura et al.,
2014). In the current study, in order to compare the protein
profiles between sensitive and resistant pair of strains, bacteria
for proteomics profiling were cultured in the absence of
antibiotics.
Ribosomal proteins (RpsS, RplF, and RpsI) were expressed
in metronidazole resistant H. pylori strains but not in sensitive
strains.
Different expressions of ribosomal proteins have been
associated with bacterial fitness (Lind et al., 2010). It has been
shown that the alteration of rplF gene (50S ribosomal protein L6)
in Escherichia colimutants interrupted cell proliferation since this
protein plays an important role in E. coli 50S subunit assembly
(Shigeno et al., 2016). Similarly, down-regulation of RpsI (30S
ribosomal protein S9) has been associated with decreasing rate
of protein synthesis in E. coli (Dabbs, 1983; Hoang et al.,
2004).
Elongation factor P (EFP), which is a prokaryotic protein
translation factor required for efficient peptide bond synthesis
on 70S ribosomes (Blaha et al., 2009), was also associated
with metronidazole resistance in H. pylori further suggesting
that protein translation were up-regulated in antibiotic resistant
strains. ATP-dependent caseinolytic proteases that acts both
as a chaperone and as an ATPase driving the degradation of
damaged or mis-made proteins has been demonstrated to play
a role in modulation susceptibility to antibiotics causing protein
damage and/or oxidative stress (Loughlin et al., 2009). From
our results, ClpP was found to be expressed in metronidazole
resistant strains indicating that the ability to degrade non-
functional proteins is an important part of the mechanism.
Thus, we hypothesized that in a dual population environment,
bacterial cells with more efficient translation machinery were
better at overcoming the action of metronidazole, which targets
bacterial DNA. This may represent an alternative mechanism
that could be used by H. pylori to counter the actions
of metronidazole. Unlike mutations in frxA and rdxA, this
alternative mechanism of metronidazole resistance will be harder
to detect.
Metabolism of Antibiotic Resistant Strains
SerA (D-3-phosphoglycerate dehydrogenase) is an enzyme
that is involved in the conversion of 3-phosphoglycerate
into 3-phosphohydroxypyruvate, one of the steps in serine
biosynthesis pathway (Shimizu et al., 2008). PyrF (orotidine 5′-
phosphate decarboxylase) is known to be an efficient enzyme
in the catalyzation of orotidine 5′-monophosphate to uridine
5′monophosphate (Harris et al., 2000) and plays a role in
pyrimidine metabolism (Capone et al., 2007). Bacteria has been
suggested of undergoing different levels of metabolism when
proteins involved in amino acid metabolism are up-regulated
(Sauer et al., 2002; Drenkard, 2003). In this study, SerA and PyrF
were shown to be associated with metronidazole resistance in H.
pylori. Alteration in metabolic pathways of antibiotic resistant
strains may be a compensatory response in order to balance
the energy production associated with antibiotic resistance. The
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higher cost of fitness needs to be compensated thus enabling a
higher survival rate of the bacteria.
CONCLUSION
Growth rates of both induced and naturally occurring
levofloxacin and metronidazole resistant strains of H. pylori
strains were comparable with their respective parental strains
indicating that the acquisition of antibiotic resistance was well-
compensated with no loss of growth fitness. However, virulence
and biofilm forming abilities were altered in certain antibiotic
resistant strains compared to their parental strains suggesting
that gain or loss of virulence and survival fitness in H. pylori is
strain specific reflecting the genetic diversity among H. pylori
strains. Our results may also suggest that in a dual population
environment, higher protein translation, and non-functional
protein degradation capabilities may be used by H. pylori to as
an alternative strategy to counter the action of metronidazole in
the absence of mutations in frxA and rdxA. In order to maintain
energy balance and fitness, metabolic pathways may be altered in
compensation. In comparison to metronidazole, compensation
for levofloxacin resistance, which involves mutations in gyrA
and gyrB, the compensatory mechanism was functionally more
random as suggested by their proteomic profiles.
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